TP53 and acute myeloid leukemia: Short DDR pulses (5–7 days) re-sensitize by collapsing S-phase checkpoints and downregulating survival transcripts like MCL1. A 2025 trial reported 40% CR in TP53-mutant, venetoclax-refractory AML with ceralasertib + venetoclax + azacitidine (Daver et al., 2025).